Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 18/20 | 0.52 |
| ▸ | JAK2 | O60674 | 13/20 | 0.52 |
| ▸ | TYK2 | P29597 | 7/20 | 0.52 |
| ▸ | JAK3 | P52333 | 12/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21904665 | 0.85 | CHEK1 (0.47) | JAK1JAK2TYK2JAK3CHEK1 | |
| SCHEMBL18538828 | 0.83 | JAK1 (0.70) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL22001611 | 0.82 | JAK1 (0.74) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL14347072 | 0.80 | JAK3 (0.63) | JAK1JAK2JAK3CHEK1AURKA | |
| SCHEMBL22349448 | 0.78 | JAK1 (0.50) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL17545975 | 0.74 | CHEK1 (0.56) | JAK1JAK2JAK3CHEK1AURKA | |
| SCHEMBL17545980 | 0.74 | CHEK1 (0.56) | JAK1JAK2JAK3CHEK1AURKA | |
| SCHEMBL22001934 | 0.73 | JAK1 (0.84) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL17545876 | 0.72 | CHEK1 (0.54) | JAK1JAK2JAK3CHEK1AURKA | |
| SCHEMBL17545887 | 0.72 | CHEK1 (0.54) | JAK1JAK2JAK3CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744136-B2 | Sulfonamide derivatives as JAK inhibitors | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744136-B2 | Sulfonamide derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | JAK1 1/4885JAK2 3/4885TYK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.